Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
Epistemonikos ID: 12747cb34dc3403cf88f70aea08e0bebb4173640
First added on: Nov 11, 2025